Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.86%) and Nasdaq Composite ( ^IXIC -1.18%) lost 0.5% and 0.9%, respectively.
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Why Teva Pharmaceutical Industries Limited’s (TEVA) Stock Is Down 13.89%
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is right time to buy.
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.
Teva Pharmaceutical Posts Lower Revenue. Stock Slips.
Teva stock fell early Wednesday after the pharma giant reported adjusted earnings of 71 cents per share on $4.23 billion in fourth-quarter sales. Please watch the video at Investors.com - How To Buy Stocks: Cup-With-Handle Chart Pattern Analysts polled by FactSet expected Teva Pharmaceutical to earn 71 cents per share on $4.
Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,
Teva Pharmaceutical shares tumble as 2025 outlook disappoints
NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below expectations.
Teva falls sharply on disappointing 2025 guidance
"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...
Teva on track for worst intraday loss in years on guidance miss
Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...
Teva price target lowered to $27 at UBS, says pullback ‘somewhat unfair’
UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.
FiercePharma21h
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
Teva price target lowered to $26 from $28 at Barclays
Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...
Teva (yes, like the sandals) makes winter boots now. We tested them in a polar vortex.
Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...
Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...